Skip to main content

Table 5 Dynamic changes of SOFA and laboratory measurements.

From: The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial

Measures

Control group

Tα1 group

Between groups difference

 

Mean (95% CI)

Mean (95% CI)

 

SOFA score

   

   Day 0

7.7 (6.8-8.5)

7.9 (7.0-8.7)

 

   Day 3

6.4 (5.6-7.2)

6.1 (5.2-6.9)

 

   Day 7

5.9 (5.0-6.7)

5.3 (4.5-6.2)

 

   ΔDay 3*

-1.3 (-1.7--0.8)a

-1.8 (-2.3--1.4)a

-0.5 (-1.2-0.1)

   ΔDay 7*

-1.8 (-2.4--1.3)a

-2.5 (-3.1--2.0)a

-0.7 (-1.5-0)

mHLA-DR (%)

   

   Day 0

58.2 (38.8-77.6)

51.8 (32.5-71.2)

 

   Day 3

62.2 (42.8-81.6)

59.8 (40.4-79.2)

 

   Day 7

69.4 (50.0-88.8)

68.9 (49.5-88.2)

 

   ΔDay 3*

4.1 (1.4-6.7)b

8.0 (5.4-10.5)b

3.9 (0.2-7.6)a

   ΔDay 7*

11.2 (7.8-14.7)b

17.0 (13.7-20.3)b

5.8 (1.0-10.5)a

CD4+/CD8+

   

   Day 0

2.4 (2.0-2.9)

2.5 (2.0-2.9)

 

   Day 3

2.7 (2.2-3.1)

2.7 (2.3-3.2)

 

   Day 7

2.4 (2.0-2.9)

2.5 (2.1-3.0)

 

   ΔDay 3*

0.2 (0-0.5)

0.3 (0-0.5)a

0 (-0.3-0.4)

   ΔDay 7*

0 (-0.3-0.3)

0.1 (-0.2-0.4)

0.1 (-0.3-0.5)

  1. * ΔDay 3 and ΔDay 7 were defined as the value changes on day 3 and day 7 compared with that on day 0. aP < 0.05; bP < 0.01. CD, cluster of differentiation; CI, confidence interval; mHLA-DR, monocyte human leukocyte antigen-DR; SOFA, Sequential Organ Failure Assessment; Tα1, thymosin alpha 1.